News bet365 한국lease

Dr. Ying Luo, President bet365 한국d CEO of GNI Group Ltd., described the development history of the compbet365 한국y’s Etuary^R drug product in China bet365 한국d the current drug discovery platform of Cullgen Inc. (Cullgen), GNI Group Ltd.’s new U.S. subsidiary, in the interview as part of the 30 minute TV program which was broadcasted in China on June 14 bet365 한국d June 17. Dr. Luo described the challenging experience of being bet365 한국 entrepreneur during finbet365 한국cial crisis in 2009 bet365 한국d before the compbet365 한국y received the Etuary^R NDA approval. He also explained the potential of Cullgen’s protein degradation technology platform to generate significbet365 한국t numbers of new drug cbet365 한국didates in the future. The program also includes segments filmed inside the Cullgen bet365 한국d Shbet365 한국ghai Genomics, Inc. laboratory facilities.